Verification evidence is still being completed.
PDF / print export
Commit Biologics ApS
Aarhus, Denmark
- Verified lead
- Thomas L. F. Montgomery Andresen
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Complement-System Immunotherapy, BiCE Engagers, and Preclinical Oncology and Autoimmune Biologics
- Review cycle
- 24 April 2026
- Full address
- Universitetsbyen 83, 8000 Aarhus C, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- GlobeNewswire release confirming Thomas L. F. Montgomery Andresen as Chief Executive Officer of Commit Biologics from March 2026.
- Editorial note
- Aarhus University spin-out in preclinical complement-engager biologics with named CEO from March 2026, BiCE platform, and a 2025 non-human primate proof-of-concept.
Complement-System Immunotherapy, BiCE Engagers, and Preclinical Oncology and Autoimmune Biologics
Public CEO disclosure via GlobeNewswire, Aarhus University spin-out recognition, Documented 2025 non-human primate proof-of-concept
Aarhus University spin-out in preclinical complement-engager biologics with named CEO from March 2026, BiCE platform, and a 2025 non-human primate proof-of-concept.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Aarhus University spin-out in preclinical complement-engager biologics with named CEO from March 2026, BiCE platform, and a 2025 non-human primate proof-of-concept.
- Lead
- Thomas L. F. Montgomery Andresen (verified ↗)
- Address
- Universitetsbyen 83, 8000 Aarhus C, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical biotech development
- Capabilities
- BiCE Complement Engager Platform · Preclinical Antibody Engineering · Oncology and Autoimmune Lead Programs
- Founded
- 2021
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Thomas L. F. Montgomery Andresen
Chief Executive Officer
Full addressUniversitetsbyen 83, 8000 Aarhus C, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
The Org headquarters listing for Commit Biologics at Universitetsbyen 83 in Aarhus.
Open sourcePreclinical biotech development
Aarhus, Denmark. Complement-System Immunotherapy, BiCE Engagers, and Preclinical Oncology and Autoimmune Biologics. Review completed on 24 Apr 2026.
Danish Medicines Agency and EMA for future clinical development
Public CEO disclosure via GlobeNewswire, Aarhus University spin-out recognition, Documented 2025 non-human primate proof-of-concept
Complement-System Immunotherapy, BiCE Engagers, and Preclinical Oncology and Autoimmune Biologics
Aarhus University spin-out in preclinical complement-engager biologics with named CEO from March 2026, BiCE platform, and a 2025 non-human primate proof-of-concept.
Editorial note
Commit Biologics is an Aarhus University spin-out with a named serial-founder CEO from March 2026, a proprietary BiCE Complement Engager platform, and a documented 2025 non-human primate proof-of-concept.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
BiCE Complement Engager Platform
Preclinical Antibody Engineering
Oncology and Autoimmune Lead Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody engineering workflow
Complement-system assays
Aarhus University collaborations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Commit Biologics ApS located?
- Commit Biologics ApS operates from Universitetsbyen 83, 8000 Aarhus C, Denmark, Aarhus, Denmark.
- Who runs Commit Biologics ApS?
- Commit Biologics ApS is led by Thomas L. F. Montgomery Andresen, Chief Executive Officer. Verified 24 Apr 2026.
- What does Commit Biologics ApS do?
- Aarhus University spin-out in preclinical complement-engager biologics with named CEO from March 2026, BiCE platform, and a 2025 non-human primate proof-of-concept. Core capabilities: BiCE Complement Engager Platform, Preclinical Antibody Engineering, Oncology and Autoimmune Lead Programs.
Editorial context
Related technical briefs
Briefs that name Aarhus as a covered market or city.